It looks more like "an acceptable tradeoff in emergent crises" than a norm. It's possible that it becomes more common, but this might mean shorter time to market for some products. It's possible we had overindexed on caution and this is a reasonable correction.
It will absolutely become more common. Launching a PR campaign to convince the public that a given disease is an "emergency" can save billions by side-stepping expensive clinical trials.
With the relatively low deadliness-to-panic ratio of COVID, the pharma industry now knows that this is possible.
I don't like that "testing in production" is now a norm in healthcare.